Prof. Xingchen Peng 彭星辰
Chief Physician, Professor
Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of head and neck tumors, breast cancer, lung cancer, colorectal cancer, gliomas, and gynecologic tumors. Specializes in radiotherapy, chemotherapy, targeted therapy, and immunotherapy for nasopharyngeal carcinoma, melanoma, and soft tissue sarcomas.
Dr. Peng is a Chief Physician, Professor, and doctoral supervisor at West China Hospital, Sichuan University. Holding a medical degree and having completed postdoctoral training at Massachusetts General Hospital, Harvard Medical School (2015–2017), Dr. Peng focuses on multimodal cancer therapy. Current responsibilities include leading multicenter clinical trials for new drugs in head and neck tumors.
Professional roles
- Chair, Cancer Prevention and Control Branch, Sichuan Medical Communication Association
- Vice Chair, Nasopharyngeal Carcinoma Committee, Sichuan Anti-Cancer Association
- Designated Chair, Skin and Soft Tissue Tumor Committee, Sichuan Oncology Society
- Vice Chair, Precision Radiotherapy Committee, Sichuan Medical Promotion Association
Name order: in Chinese the family name comes first (Peng Xingchen). Papers usually list the name as Xingchen Peng or Peng X.
Selected publications
214 papers on PubMed matched by name and affiliation; 114 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biomaterials, 2026 (senior author): Manganese@Gold cluster-coordinated covalent organic frameworks-based artificial metalloenzymes with cascade biocatalysis and amplified systemic stimulation to combat malignant tumor metastasis. PubMed 42402240
- Cancer Med, 2026 (senior author): Opportunities and Challenges in FLASH Radiotherapy: Focusing on Normal Tissue Protection Effects and Clinical Translation Bottleneck. PubMed 42984403
- Redox Biol, 2026 (senior author): State-matched redox nanomedicine for cell fate control and multicompartment therapeutic windows. PubMed 42837695
- Arch Oral Biol, 2026 (senior author): Decoding the molecular landscape of radiation-induced oral mucositis: Integrated molecular networks and therapeutic targets. PubMed 42981660
- Adv Sci (Weinh), 2026 (senior author): Biomimetic Nanoplatform for Fibrosis Remodeling and Anti-PD-1 Potentiation via Cu(+)/Ca(2+) Ion Dysregulation and TGF-β Inhibition in PDAC. PubMed 42919437
- Exp Hematol Oncol, 2026 (senior author): Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation. PubMed 42919351
- Head Neck, 2026 (senior author): Trajectories of Plasma Epstein-Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD-L1 Inhibitors: A Post-Hoc Analysis of a Multicenter, Phase II Study. PubMed 42860770
- Quant Imaging Med Surg, 2026 (senior author): Utilization of (68)Ga-FAPI PET/CT improves the gross tumor volume delineation in nasopharyngeal carcinoma within a safe radiation dose to organs at risk. PubMed 42861158
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion